This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Olink Holding Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jon Heimer

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage	27.7%
CEO tenure	3.6yrs
CEO ownership	2.5%
Management average tenure	1.6yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jon Heimer's remuneration changed compared to Olink Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$34m
Dec 31 2023	US$2m	US$423k	-US$32m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$2m	US$416k	-US$13m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$35m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$708k	US$432k	-US$43m

Compensation vs Market: Jon's total compensation ($USD1.52M) is about average for companies of similar size in the German market ($USD2.01M).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Heimer (57 yo)

3.6yrs

Tenure

US$1,523,605

Compensation

Mr. Jon Heimer serves as the Chairman of Olink Proteomics AB since 2014 and its Chief Executive Officer since January 2016. He serves as Director of Olink Holding AB (publ) since December 2020 and serves a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jon Heimer	CEO & Director	no data	US$1.52m	2.49% $ 74.6m
Carl Raimond	Interim Chief Commercial Officer & President	1.6yrs	no data	0.21% $ 6.3m
Oskar Hjelm	Chief Financial Officer	4.3yrs	no data	0.18% $ 5.3m
Anna Marsell	Chief Operating Officer	1.6yrs	no data	0.0016% $ 47.1k
Linda Ramirez-Eaves	General Counsel	5.4yrs	no data	0.019% $ 564.7k
Andrea Prander	Corporate Communications Manager	no data	no data	no data
Elias Berglund	Chief People Officer	1.2yrs	no data	0% $ 0
Rickard El Tarzi	Chief Strategy & Product Officer	4.4yrs	no data	0.28% $ 8.3m
Maria Bjork	Chief Research & Development Officer	less than a year	no data	0.00020% $ 6.0k
Stina Thorman	Investor Relations Officer	no data	no data	no data

1.6yrs

Average Tenure

49yo

Average Age

Experienced Management: 6XA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jon Heimer	CEO & Director	3.6yrs	US$1.52m	2.49% $ 74.6m
Jon Hindar	Independent Chairman of the Board	3.5yrs	US$258.45k	0.17% $ 5.0m
Nicolas Roelofs	Independent Director	3.6yrs	US$148.37k	0.12% $ 3.7m
Robert Schueren	Independent Director	2.3yrs	US$139.04k	0.0019% $ 56.4k
Tommi Unkuri	Director	5.3yrs	no data	no data
Solange Bullukian	Independent Director	3.5yrs	US$178.37k	0.016% $ 477.5k
Mary Reumuth	Independent Director	2.3yrs	US$139.04k	0.0019% $ 56.4k
Johan Lund	Independent Director	3.6yrs	US$168.37k	0.049% $ 1.5m
Gregory Moore	Director	1.3yrs	US$89.60k	0% $ 0
Johan Holmner	Deputy Board Member	no data	no data	no data

3.5yrs

Average Tenure

60yo

Average Age

Experienced Board: 6XA's board of directors are considered experienced (3.5 years average tenure).

This company listing is no longer active

Olink Holding Management

Management criteria checks 3/4

Key information

Recent management updates

Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024

Olink Holding AB Announces Promotion of Maria Liminga Björk to Chief Research and Development Officer

High number of new and inexperienced directors

Olink Holding AB (Publ) Announces Management Appointments

High number of new and inexperienced directors

Olink Holding AB (publ) Announces Board Appointments

Recent updates

Olink Holding AB (publ)(NasdaqGM:OLK) dropped from NASDAQ Composite Index

Forecast breakeven date moved forward to 2024

Olink Holding AB (publ)(NasdaqGM:OLK) dropped from S&P Global BMI Index

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others.

Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute Confidence

Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 loss in 1Q 2023)

Forecast breakeven date pushed back to 2025

Full year 2023 earnings released: US$0.25 loss per share (vs US$0.11 loss in FY 2022)

Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024

Olink Holding AB Announces Promotion of Maria Liminga Björk to Chief Research and Development Officer

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.011 loss in 3Q 2022)

Olink Holding AB (publ) to Report Q3, 2023 Results on Nov 15, 2023

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Olink Holding AB (publ) Demonstrates the Power of the Olink Explore Platform for Driving Impactful Proteogenomic Studies At the Population Scale

Olink Holding AB (Publ) Announces the Introduction of Olink(R) Target 48 Mouse Cytokine Panel

Forecast breakeven date moved forward to 2024

Olink Holding AB (Publ) Reiterates Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.067 loss per share (vs US$0.04 loss in 2Q 2022)

Olink Holding AB (publ) to Report Q2, 2023 Results on Aug 09, 2023

Olink Holding AB (Publ) Announces the Introduction of Olink(R) Explore Ht

Now 21% undervalued

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.10 loss in 1Q 2022)

Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2023

Now 24% undervalued after recent price drop

Forecast to breakeven in 2024

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.43 loss in FY 2021)

Now 20% undervalued

Olink Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Now 22% undervalued

Third quarter 2022 earnings released: US$0.011 loss per share (vs US$0.046 loss in 3Q 2021)

High number of new and inexperienced directors

Olink® Flex, A New, Unique and Fully Flexible Low-Plex Proteomics Solution Using Absolute Quantification

Third quarter 2022 earnings released: US$0.01 loss per share (vs US$0.046 loss in 3Q 2021)

Olink Holding AB (publ) Provides Earnings Guidance for the Full Year 2022

Olink Holding AB (Publ) Announces the Launch of Olink(R) Insight

Olink Holding AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Olink Holding AB (Publ) Announces Management Appointments

Second quarter 2022 earnings released: US$0.04 loss per share (vs US$0.089 loss in 2Q 2021)

Olink Holding AB (Publ) Provides Revenue Guidance for the Fiscal Year 2022

Olink Holding AB (publ) to Report Q2, 2022 Results on Aug 11, 2022

Release of Olink Analyze 3.1 Streamlines Proteomic Analysis to Connect Data to Biological Insight

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.48 loss in 1Q 2021)

Olink Holding AB (publ) Provides Revenue Guidance for the Year 2022

Forecast breakeven date moved forward to 2023

High number of new and inexperienced directors

Olink Holding AB (publ) to Report Q1, 2022 Results on May 12, 2022

Forecast to breakeven in 2024

Olink Holding AB (publ) Announces Board Appointments

Olink Holding AB (publ) Provides Revenue Guidance for 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Olink Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2022

High number of new and inexperienced directors

Olink Holding AB (Publ) Announces Delivery of Olink® Explore 3072 Is Now Starting

Olink Holding AB (publ) Announces Delivery of Olink® Signature Q100

Third quarter 2021 earnings released: US$0.046 loss per share

Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021

Olink Holding AB (publ) Announces UK Biobank Pharma Proteomics Project's Expansion of Ongoing Proteomics Study Of 53,000 Participants to the New Olink Explore 3072 Platform

Olink Holding AB (publ) has completed a Follow-on Equity Offering in the amount of $232.5 million.

Olink Holding AB (publ) Provides Preliminary Unaudited Earnings Guidance for the Second Quarter Ended June 30, 2021

Olink Announces the New Explore 3072 High Throughput Proteomics Platform

SCALLOP Launches Clinical Trial Arm to Uncover Next Level of Drug Target Insights from Proteomic Profiling

Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021

Olink Announces First Core Lab Running the Olink Explore Platform in Europe, Making It Available for More Researchers

CEO Compensation Analysis

CEO

Tenure